公开(公告)号：US20090241202A1

公开(公告)日：2009-09-24

申请号：US12095822

申请日：2006-12-14

申请人： Peter Kufer ,  Tobias Raum ,  Petra Lutterbüse ,  Bernd Schlereth ,  Klaus Brischwein ,  Robert Hofmeister

发明人： Peter Kufer ,  Tobias Raum ,  Petra Lutterbüse ,  Bernd Schlereth ,  Klaus Brischwein ,  Robert Hofmeister

IPC分类号： A61K49/00 ,  C07K16/00 ,  C12N15/63 ,  C12N5/00 ,  C12P21/00

CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K16/462 ,  C07K2317/732

摘要： The present invention relates to antibodies. Specifically, the present invention relates to antibodies composed of novel combinations of inter-species antibody domains (“domain-grafted antibodies”). The present invention further relates to compositions comprising such domain-grafted antibodies, as well as methods for producing such domain-grafted antibodies. Finally, the present invention relates to methods of evaluating the in vivo biological effect of such domain-grafted antibodies as well as uses of such domain-grafted antibodies for cross-species evaluation of the in vivo activity antibodies intended for human therapy.

摘要翻译： 本发明涉及抗体。 具体地，本发明涉及由物种间抗体结构域（“结构域接枝抗体”）的新型组合构成的抗体。 本发明还涉及包含这种结构域接枝抗体的组合物，以及生产这种结构域接枝抗体的方法。 最后，本发明涉及评价这种结构域接枝抗体的体内生物学效应的方法以及这种结构域接枝抗体用于物种评价用于人类治疗的体内活性抗体的用途。

公开(公告)号：US08236308B2

公开(公告)日：2012-08-07

申请号：US12083351

申请日：2006-10-10

申请人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

发明人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

IPC分类号： A61K39/395

CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/622

摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

摘要翻译： 本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。 本发明还涉及用于评估展示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。 本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。 此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

公开(公告)号：US20090252683A1

公开(公告)日：2009-10-08

申请号：US12083351

申请日：2006-10-10

申请人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

发明人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/13 ,  C12N15/85 ,  C12N5/16 ,  C12P21/02 ,  A61P35/00 ,  A61B10/00

CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/622

摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

摘要翻译： 本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。 本发明还涉及用于评估展示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。 本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。 此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

公开(公告)号：US20130129729A1

公开(公告)日：2013-05-23

申请号：US13567672

申请日：2012-08-06

申请人： Roman KISCHEL ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

发明人： Roman KISCHEL ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/46

CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/622

摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

摘要翻译： 本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。 本发明还涉及用于评估显示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。 本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。 此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

公开(公告)号：US20080044413A1

公开(公告)日：2008-02-21

申请号：US11645290

申请日：2006-12-21

申请人： Scott Hammond ,  Peter Kiener ,  Elizabeth Bruckheimer ,  Michael Kinch ,  Shannon Roff ,  Ralf Lutterbuese ,  Petra Lutterbuese ,  Bernd Schlereth ,  Patrick Baeuerle ,  Peter Kufer

发明人： Scott Hammond ,  Peter Kiener ,  Elizabeth Bruckheimer ,  Michael Kinch ,  Shannon Roff ,  Ralf Lutterbuese ,  Petra Lutterbuese ,  Bernd Schlereth ,  Patrick Baeuerle ,  Peter Kufer

IPC分类号： A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P43/00 ,  C07K16/28

CPC分类号： C07K16/2866 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  C07K2319/30

摘要： The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs. The invention also provides compositions, including pharmaceutical compositions, comprising any of the aforementioned EphA2-BiTEs, polynucleotides or vectors either alone or in combination with one or more prophylactic or therapeutic agents. Also disclosed are methods of screening for said EphA2-BiTEs and kits comprising any of the aforementioned compositions and diagnostic reagents.

摘要翻译： 本发明涉及双特异性单链抗体，其包含免疫特异性结合T细胞抗原CD3的第一结合结构域和免疫特异性结合EphA2受体的第二结合结构域。 这种双特异性单链抗体包括在术语“EphA2-BiTEs”中。 本发明还涉及设计用于治疗，预防和/或控制与EphA2的异常表达和/或活性相关的病症的方法和组合物。 这些疾病包括但不限于癌症，非癌症过度增殖性细胞病症和感染。 本发明还涉及包含编码本发明的EphA2-BiTE的多核苷酸，转化的宿主细胞的载体及其在所述EphA2-BiTE的生产中的用途。 本发明还提供包含单独或与一种或多种预防或治疗剂组合的任何上述EphA2-BiTE，多核苷酸或载体的组合物，包括药物组合物。 还公开了筛选所述EphA2-BiTE和包含任何上述组合物和诊断试剂的试剂盒的方法。